Navigation Links
Rigel Announces First Quarter 2009 Financial Results
Date:5/5/2009

SOUTH SAN FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2009.

For the first quarter of 2009, Rigel reported a net loss of $29.9 million, or $0.82 per share, compared to a net loss of $27.3 million, or $0.79 per share, in the first quarter of 2008. Weighted average shares outstanding for the first quarters of 2009 and 2008 were 36.7 million and 34.4 million, respectively.

Rigel reported total operating expenses of $30.3 million in the first quarter of 2009, compared to $28.7 million in the first quarter of 2008. The increase in operating expenses was primarily due to increases in clinical development and restructuring costs, partially offset by the decrease in stock-based compensation expense. The increase in clinical development expenses was primarily due to the costs associated with the Company's two Phase 2b clinical trials of R788 in rheumatoid arthritis (TASKi2 and TASKi3). As a result of the restructuring implemented in the first quarter of 2009, Rigel recorded restructuring charges of $1.1 million which consisted primarily of severance payments and extended health benefits for the affected employees. Stock-based compensation expenses decreased from $5.8 million in the first quarter of 2008 to $2.3 million in the first quarter of 2009, primarily due to the higher valuation of options granted in the first quarter of 2008 and the full expense recognition of the majority of those options by the end of 2008.

In the first quarter of 2009, Rigel recorded a federal refundable tax benefit of approximately $66,000, which was calculated in accordance with The American Recovery and Reinvestment Act of 2009.

As of March 31, 2009, Rigel had cash, cash equivalents and available for
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Rigel to Present at BIO Investor Forum 2007
2. Rigel to Present Research Programs at Scientific Conferences
3. Rigel Announces Pricing of Public Offering of Common Stock
4. Rigel to Present at BIO CEO & Investor Conference
5. Rigel Announces Fourth Quarter and Year End 2007 Financial Results
6. Rigel to Host Update Conference Call
7. Rigel Announces Third Quarter 2008 Financial Results and Clinical Update
8. Rigel to Present at the 2008 Credit Suisse Healthcare Conference
9. Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
10. Rigel to Participate at the RBC Capital Markets Healthcare Conference
11. Rigel to Present at Citis Biotech Day
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... Research and Markets  has announced ... (Biodegradable Polymer, Food & Beverage, Personal Care & ... report to their offering. Lactic ... asymmetrical carbon atom. The main applications of lactic ... beverage, personal care product, and pharmaceutical industries. ...
(Date:8/27/2014)... 2014 “We are honored to be ... Ven Thangaraj, CEO of Radiant Sage. “We are offering ... the imaging corelab market to a different level. ... organizations to efficiently and effectively manage the massive amounts ... be analyzed and read by trained physicians. Being recognized ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Flagship Biosciences ... services to the pharmaceutical and medical device industries, ... The fast growing company has consolidated its histology ... and Boulder to Westminster, CO, just north of Denver. ... Lab, 7575 W. 103rd Ave., Suite 100, Westminster, CO ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture ... firms investing in the development of seed and ... eighth venture fund closed with more than $400 ... its $250 million subscription target by more than ... VIII shows the strength and potential of our ...
Breaking Biology Technology:Global Lactic Acid (Biodegradable Polymer, Food & Beverage, Personal Care & Pharmaceutical) Market - Trends & Forecasts to 2019 2Radiant Sage Named to CIOReview List of 100 Most Promising Technology Companies 2Flagship Biosciences Announces Relocation and Expansion 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... today that Battelle, a science and technology development ... closing its,operations. Financial terms of the acquisition were ... Battelle to transition our assets. In,addition, we will ... our employees," said Leslie Williams, President and CEO,of ...
... BOULDER, Colo., Oct. 29 /PRNewswire/ - N30 Pharma ... and,commercialization of respiratory drugs that target endogenous,s-nitrosothiols, today ... NTMD ) covering the respiratory use of a ... not disclosed. "I am extremely pleased to ...
... 29 Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced ... financial results after the Nasdaq market closes on Thursday,November ... be held at 5:00,p.m. Eastern Time (2:00 p.m. Pacific ... by dialing,1-800-894-5910, (US) or 785-424-1052 (International) using the conference,ID: ...
Cached Biology Technology:Ventaira Pharmaceuticals Announces Acquisition of Assets by Battelle 2
(Date:8/27/2014)... advocates, campaigns against trans-fats have largely succeeded in ... aim at sugar for its potential contributions to ... still wrangling over the best way to assuage ... article in Chemical & Engineering News ... Chemical Society. , In the article, Stephen Ritter, ...
(Date:8/27/2014)... of Adelaide research has shown that piglets can be ... frequency. , The outcome of the study at the ... Reproduction Science , is an important finding for pig ... without loss of production. , "Sows don,t usually start ... heat after their piglets have been weaned," says Ms ...
(Date:8/27/2014)... Gamblers are greedy bird-brains, University of Warwick research finds ... when they make risky decisions, new research has shown. ... University of Warwick,s Department of Psychology, conducted tests that ... more likely to gamble for high-value than low-value rewards. ... argue that the test results show the important role ...
Breaking Biology News(10 mins):Piglet weaning age no bar to litter frequency 2Gamblers are greedy bird-brains, University of Warwick research finds 2
... The American Society for Bone and Mineral Research (ASBMR) ... the world on bone and mineral metabolism, offering an ... new clinical treatments in bone diseases and disorders of ... being held in Baltimore, MD USA, October 4 ...
... immediately in low-resource countries, could have the potential to save ... 2015. Right now the annual global death toll ... Between 2016-2020, these innovations have the potential to save ... The ten, identified by international experts from hundreds of candidates, ...
... dioxide a common ingredient in cosmetics, food products, ... risks associated with the widely used compound. The report ... every year for the global market, appears in the ... Francesco Turci and colleagues explain that titanium dioxide (TiO2) ...
Cached Biology News:American Society for Bone and Mineral Research Annual Meeting Oct. 4-7 2Innovations save lives of mothers and children 2Innovations save lives of mothers and children 3Innovations save lives of mothers and children 4Innovations save lives of mothers and children 5Innovations save lives of mothers and children 6Innovations save lives of mothers and children 7